Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Owkin
HQ France · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Sep 2025: Owkin planned to cut about 50 of 325 jobs via a voluntary departure scheme as it refocused on AI; in Mar 2026 it spun out its diagnostics unit as Waiv with $33m of external financing.
Cyber & information governance
No data breaches, cyber incidents or regulator (e.g. CNIL) actions involving Owkin found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No recalls, safety notices or regulator actions involving Owkin found in HSH's search of the last 24 months. Its CE-marked AI pathology diagnostics moved to spin-out Waiv, which reported IVDR CE marking in Apr 2026.
Contract performance
May 2026: Owkin and AstraZeneca expanded their AI collaboration with a multi-year research agreement for Owkin's K Pro platform. No customer disputes or terminations found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.